allogeneic HSCT recipients and immunodeficient patients.
in this patient population treatment with infusions of these EBV-specific T cells.
disease risk (high vs low).
dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
or unrelated donor matched for at least 2 HLA alleles may be used.